ISSN:
1573-7241
Keywords:
PAF antagonists
;
heart-lung transplantation
;
ischemia-reperfusion injury
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract The objective of this experimental protocol was to evaluate theprotective effect of a new, potent platelet-activating factor (PAF)antagonist CV-6209 and the use of this compound in combination withallopurinol on ischemia-reperfusion injury in a swine model of heart-lungtransplantation. Forty-two swine were divided into three groups, with sevendonors and seven recipients in each. In group A, the PAF antagonist CV-6209was administered in a single dosage of 1 mg/kg by slow intravenousinjection at 1 hour before crossclamping of the aorta in both donors andrecipients. In group B the combination of allopurinol and the PAFantagonist CV-6209 was used. Allopurinol was administered as a pretreatmentregime of 50 mg/kg/day for 3 days prior to ischemia. The PAFantagonist dosage and regime of administration were the same as in group A,and both donors and recipients were pretreated with this combination. GroupC was the control in which heart-lung transplantations were performedwithout interventional therapies. Based on the comparison of pre- andpost-transplantation assessments of cardiac and pulmonary functionalintegrity within groups, and post-transplantation among groups, animals ingroups A and B were significantly (P 〈 0.05) better protected fromischemia-reperfusion injury than animals in group C. The difference betweengroups A and B, however, was insignificant at all times. Morphologicalfindings are in agreement with measures of physiological variation amongexperimental groups. It is suggested that the new PAF antagonist CV-6209 iseffective in the prevention of heart and lung ischemia-reperfusion injurywith and without allopurinol pretreatment.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1007718309177
Permalink
